Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
Nektar Therapeutics Announces Proposed Public Offering
04:02pm, Monday, 30'th Jun 2025
SAN FRANCISCO , June 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherap
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
02:21pm, Monday, 30'th Jun 2025
The biopharmaceuticals space is notorious for sudden, sharp rallies, and for precipitous sell-offs as well. The industry is crowded with names, many of which are tiny firms working toward developing a
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
08:15am, Saturday, 28'th Jun 2025
On June 24, Nektar Therapeutics NASDAQ: NKTR stock exploded nearly 157% following news that Rezpeg, the company's experimental treatment for atopic dermatitis (eczema), successfully met its primary a
Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg
08:45am, Friday, 27'th Jun 2025
Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg
Why Nektar Therapeutics Stock Was Red-Hot Today
06:45pm, Wednesday, 25'th Jun 2025
The latest biotech stock to explode in price, Nektar Therapeutics (NKTR 19.10%) was quite the outperformer on the stock exchange for the second day in a row. On Wednesday, one day after delivering ex
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
01:42pm, Wednesday, 25'th Jun 2025
Nektar Therapeutics NKTR released on Tuesday statistically significant data from the 16-week induction period of the ongoing Phase 2b REZOLVE-AD study of investigational rezpegaldesleukin.
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study
12:31pm, Wednesday, 25'th Jun 2025
Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.
Nektar Therapeutics Is Up 150%: What's Happening With NKTR Stock?
01:20pm, Tuesday, 24'th Jun 2025
Nektar Therapeutics (NASDAQ: NKTR) stock is up around 150% in today's trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin for trea
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
11:41am, Tuesday, 24'th Jun 2025
Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the
Biotech Stocks Blasts Off After Eczema Drug Trial
10:53am, Tuesday, 24'th Jun 2025
Biotech stock Nektar Therapeutics Inc (NASDAQ:NKTR) is soaring today, up 83.7% at $17.52 at last glance, after the company's eczema drug, rezpegaldesleukin, met its primary and secondary goals in a mi
Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial
07:35am, Tuesday, 24'th Jun 2025
Nektar Therapeutics said on Tuesday its experimental eczema drug had met the main goals of a mid-stage study.
Achieved statistical significance on primary endpoint at week 16 for mean percent change in EASI score from baseline for all rezpegaldesleukin arms versus placebo Achieved statistical significance fo
SAN FRANCISCO , June 23, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will
Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC
03:13pm, Wednesday, 11'th Jun 2025
Results from Nektar Therapeutics' phase 2b REZOLVE-AD study, using REZPEG for the treatment of patients with atopic dermatitis, are expected in June 2025. The global atopic dermatitis treatment market
AMBROSIA & NEKTAR Introduces Premium High-End Organic Food from Greece with a Commitment to Purity and Provenance
05:26pm, Tuesday, 10'th Jun 2025
Brand emphasizes absolute transparency and traceability, sourcing single-ingredient food from small artisan producers Brand emphasizes absolute transparency and traceability, sourcing single-ingredien
